Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | MTOR | P42345 | 2/20 | 0.54 |
| ▸ | PRKDC | P78527 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | PRKCG | P05129 | 1/20 | 0.51 |
| ▸ | PRKCB | P05771 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | PRKCH | P24723 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26697988 | 0.89 | OPRM1 (0.54) | HSD11B1PIK3CAMTORPRKDCGPR119 | |
| SCHEMBL29171247 | 0.85 | PIK3CA (0.52) | HSD11B1PIK3CAMTORPRKDCGPR119 | |
| SCHEMBL8063089 | 0.85 | OPRM1 (0.50) | GPR119CYP3A4PRKCGPRKCBPRKCA | |
| SCHEMBL17803254 | 0.85 | HSD11B1 (0.61) | HSD11B1PIK3CAMTORPRKDCKDM4E | |
| SCHEMBL7596262 | 0.84 | OPRM1 (0.49) | PIK3CAMTORPRKDCGPR119CYP3A4 | |
| SCHEMBL3764320 | 0.84 | PIK3CA (0.51) | HSD11B1PIK3CAMTORPRKDCGPR119 | |
| SCHEMBL10145862 | 0.84 | PIK3CA (0.51) | HSD11B1PIK3CAMTORPRKDCGPR119 | |
| SCHEMBL3098947 | 0.83 | CYP2D6 (0.57) | GPR119CYP3A4PRKCGPRKCBPRKCA | |
| SCHEMBL11030825 | 0.83 | CHRM2 (0.51) | PIK3CAMTORPRKDCGPR119PRKCG | |
| SCHEMBL8103415 | 0.83 | OPRL1 (0.53) | GPR119OPRM1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848598-B | Heterocyclic compound, application thereof and composition containing same | 健艾仕生物医药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | GENEROS BIOPHARMA LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
| CN-111848598-A | Heterocyclic ring-containing compound, application thereof and composition containing heterocyclic ring-containing compound | 健艾仕生物医药有限公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-7879880-B2 | such as [4-[(2-aminopyridin-4-yl)methyl]piperazin-1-yl]-[4-(pyridin-4-ylamino)phenyl]methanone, used for the treatment of inflammatory diseases, allergic conditions, diabetes, obesity, metabolic syndrome, cognition disorder, cardiovascular and nervous system disorders | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100173941-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173941-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| WO-2007142584-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007075688-A2 | SUBSTITUTED ANILINE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070142394-A1 | Substituted aniline derivatives useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| EP-0828754-B1 | DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE | PFIZER (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2002100861-A1 | 1-(3-PHENYLOXYPROPYL)PIPERIDINE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2002-12-19 | — | — | WO | disclosed |
| US-5936089-A | PIPERIDINE DERIVATIVES; BONE DISORDERS; OBESITY; AGING; CACHEXIA ASSOCIATED WITH AIDS AND CANCER | PFIZER INC (US) | 1999-08-10 | — | — | US | disclosed |
| US-5760054-A | BENIGN PROSTATIC HYPERTROPHY | MERCK & CO., INC. (US) | 1998-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099441-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | STAT5A, STAT5B, JAK2 | HSD11B1 525/4885PIK3CA 407/4885MTOR 61/4885 |
| US-20070142394-A1 | Substituted aniline derivatives useful as histamine H3 antagonists | HRH3, CHRM2, HCRTR2 | HSD11B1 650/4885PIK3CA 3744/4885MTOR 1866/4885 |
| US-20100173941-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | CHRM1, CHRM2, CHRM5 | HSD11B1 2238/4885PIK3CA 3804/4885MTOR 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.